Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis

Clinical and Experimental Immunology

Volumn 152, Issue 2, 2008, Pages 328-335

  Kim, J Y ^a   Kwok, S K ^a   Hur, K H ^a   Kim, H J ^a   Kim, N S ^a   Yoo, S A ^a   Kim, W U ^a   Cho, C S ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Dermal fibroblasts; Macrophage migration inhibitory factor; Systemic sclerosis; T cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITROPRUSSIDE SODIUM; PROTEIN BCL 2; PROTEIN KINASE B;

ADULT; APOPTOSIS; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; WESTERN BLOTTING;

ADULT; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EIF-2 KINASE; FEMALE; FIBROBLASTS; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NITROPRUSSIDE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 42049084644     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03637.x     Document Type: Article

References (46)

1. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996 39 : 1338 46.
2. Botstein GR, Sherer GK, LeRoy EC. Fibroblast selection in scleroderma: an alternative model of fibrosis. Arthritis Rheum 1982 25 : 189 95.
3. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974 54 : 880 9.
4. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001 44 : 1667 76.
5. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000 43 : 2230 9.
6. Tamm I, Kikuchi T, Zychlinsky A. Acidic and basic fibroblast growth factors are survival factors with distinctive activity in quiescent BALB/c 3T3 murine fibroblasts. Proc Natl Acad Sci USA 1991 88 : 3372 6.
7. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994 13 : 3286 95.
8. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966 153 : 80 2.
9. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966 56 : 72 7.
10. Baumann R, Casaulta C, Simon D, Conus S, Yousefi S, Simon HU. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J 2003 17 : 2221 30.
11. Riedemann NC, Guo RF, Gao H et al. Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J Immunol 2004 173 : 1355 9.
12. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994 179 : 1895 902.
13. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998 10 : 199 205.
14. Hayashi T, Nishihira J, Koyama Y, Sasaki S, Yamamoto Y. Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. J Invest Dermatol 2006 126 : 990 7.
15. Leech M, Metz C, Santos L et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998 41 : 910 7.
16. Morand EF, Bucala R, Leech M. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. Arthritis Rheum 2003 48 : 291 9.
17. Leech M, Metz C, Hall P et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999 42 : 1601 8.
18. de Jong YP, Abadia-Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001 2 : 1061 6.
19. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neurol Sci 2000 179 : 70 5.
20. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004 31 : 268 73.
21. Donn RP, Plant D, Jury F et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004 123 : 484 7.
22. Selvi E, Tripodi SA, Catenaccio M et al. Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 2003 62 : 460 4.
23. Wu SP, Leng L, Feng Z et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006 54 : 3661 9.
24. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003 3 : 791 800.
25. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999 274 : 18100 6.
26. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S. Macrophage migration inhibitory factor (MIF). Its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 2003 995 : 171 82.
27. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999 190 : 1375 82.
28. Fingerle-Rowson G, Petrenko O, Metz CN et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003 100 : 9354 9.
29. Petrenko O, Fingerle-Rowson G, Peng T, Mitchell RA, Metz CN. Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem 2003 278 : 11078 85.
30. American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 23 : 581 90.
31. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002 168 : 3649 59.
32. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003 15 : 691 9.
33. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000 275 : 10761 6.
34. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005 9 : 59 71.
35. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005 202 : 1363 74.
36. Chadha KS, Khoury T, Yu J et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006 13 : 933 9.
37. Takahashi N, Nishihira J, Sato Y et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998 4 : 707 14.
38. Leung JC, Chan LY, Tsang AW et al. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrol Dial Transplant 2004 19 : 1976 85.
39. Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 1997 40 : 540 50.
40. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992 27 : 169 77.
41. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999 11 : 503 7.
42. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanism of pathogenesis in scleroderma. Overproduction of interleukin 6 by fibroblast cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992 19 : 1207 11.
43. Leech M, Lacey D, Xue JR et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003 48 : 1881 9.
44. Lacey D, Sampey A, Mitchell R et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003 48 : 103 9.
45. Tourkina E, Gooz P, Pannu J et al. Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005 280 : 13879 87.
46. Jun JB, Kuechle M, Min J et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005 124 : 298 303.